

AMENDMENTS

In the claims:

1. (Original) A method for modulating tumor growth or metastasis in an animal in need thereof, comprising sequential or simultaneous administration of at least one anticancer agent, and a combretastatin A-4 compound in amounts effective therefor.
2. (Original) A method for modulating tumor growth or metastasis in an animal in need thereof, comprising administration of a combretastatin A-4 compound and at least one anticancer agent, in amounts effective therefor, wherein said combretastatin A-4 compound is administered at a time relative to administration of said anticancer agent sufficient to modulate blood flow to said tumor to provide a time-dependent effective tumor concentration of said anticancer agent.
3. (Previously presented) The method as claimed in claim 1, wherein said at least one anti-cancer agent is a mitotic inhibitor.
4. (Previously presented) The method as claimed in claim 1, wherein said at least one anticancer agent is selected from the group consisting of paclitaxel and docetaxel.
- 5.-6. (Cancelled)
7. (Previously presented) The method as claimed in claim 1 wherein said anticancer agent is a duration exposure agent and is administered sequentially in any order with said combretastatin A4 compound.
8. (Previously presented) The method as claimed in claim 7, wherein said duration exposure agent is a taxane.
- 9.-13. (Cancelled)

14. (Previously presented) The method as claimed in claim 8, wherein said combretastatin A4 compound is a combretastatin A-4 phosphate prodrug salt and said taxane is paclitaxel.

15. (Previously presented) The method as claimed in claim 14, wherein said combretastatin A4 phosphate prodrug salt is administered at least 3 hours prior to paclitaxel.

16.-21. (Cancelled)

22. (Original) A pharmaceutical composition for modulating tumor growth or metastasis in an animal in need thereof, comprising at least one anticancer agent, and a combretastatin A-4 compound, in amounts effective therefore in a pharmaceutically acceptable carrier.

23. (Previously presented) The pharmaceutical composition as claimed in claim 22, wherein said at least one anticancer agent is a taxane.

24. (Previously presented) The pharmaceutical composition of claim 23, wherein said combretastatin A-4 compound is a combretastatin A-4 phosphate prodrug salt.

25.-36. (Cancelled)

37. (Previously presented) The pharmaceutical composition as claimed in claim 23, wherein said taxane is paclitaxel.

38. (Previously presented) The pharmaceutical composition as claimed in claim 24, wherein said taxane is paclitaxel.

39-60. (Cancelled)

61.-76. (Cancelled)